Bevacizumab

Nat Rev Drug Discov. 2005 May:Suppl:S8-9. doi: 10.1038/nrd1727.

Abstract

Bevacizumab (Avastin; Genentech/Roche), an antibody against vascular endothelial growth factor, was approved by the US FDA in February 2004 for the first-line treatment of metastatic colorectal cancer in combination with 5-fluorouracil-based chemotherapy. It is the first approved agent to target tumour angiogenesis.

Publication types

  • Review

MeSH terms

  • Angiogenesis Inhibitors / therapeutic use*
  • Antibodies, Monoclonal / administration & dosage
  • Antibodies, Monoclonal / therapeutic use*
  • Antibodies, Monoclonal, Humanized
  • Antineoplastic Agents / administration & dosage
  • Antineoplastic Agents / therapeutic use*
  • Bevacizumab
  • Clinical Trials as Topic
  • Colorectal Neoplasms / blood supply
  • Colorectal Neoplasms / drug therapy*
  • Humans
  • Treatment Outcome
  • Vascular Endothelial Growth Factor A / antagonists & inhibitors

Substances

  • Angiogenesis Inhibitors
  • Antibodies, Monoclonal
  • Antibodies, Monoclonal, Humanized
  • Antineoplastic Agents
  • Vascular Endothelial Growth Factor A
  • Bevacizumab